Patients who are human immunodeficiency virus (HIV) positive on highly active anti-retroviral therapy (HAART) will be excluded from the study
Patients known to be human immunodeficiency (HIV)-positive receiving anti-retroviral therapy are excluded from the study
Not compliant with anti-retroviral therapy (HIV infected participants)
Human immunodeficiency virus (HIV)-positive patients receiving anti-retroviral therapy are excluded from this study; HIV positive patients not receiving antiretroviral therapy are excluded
Human immunodeficiency virus (HIV)-positive patients receiving anti-retroviral therapy are excluded from this study
Human immunodeficiency virus (HIV)-positive patients receiving anti-retroviral therapy are excluded from this study; HIV positive patients not receiving antiretroviral therapy are excluded
Known HIV-positive subjects on combination anti-retroviral therapy due to the potential for PK interactions with the study agent.
If HIV positive, receipt of anti-retroviral therapy continuously for at least  months prior to enrollment
Patient on anti-retroviral medications
Patients known to be human immunodeficiency virus (HIV) positive who are not receiving anti-retroviral therapy will be excluded
Has a known history of human immunodeficiency virus (HIV); HIV-positive patients receiving anti-retroviral therapy are excluded from this study; HIV positive patients not receiving antiretroviral therapy are excluded
Known positive serology for human immunodeficiency virus (HIV), due to potential drug-drug interactions between anti-retroviral medications and the study drugs
Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study
Human Immunodeficiency Virus (HIV)-infection is not an exclusion criterion if it is controlled with anti-retroviral drugs that are unaffected by concomitant enzalutamide.
Known human immunodeficiency virus (HIV)-positive patients are excluded from the study; for patients receiving combination anti-retroviral therapy; screening for HIV status will not be performed
Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded
Known HIV positive or on active anti-retroviral therapy
Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome. Anti-retroviral agents are known to have potential adverse pharmacokinetic interactions with nivolumab and/or BMS-. IN addition, patients not on anti-retroviral agents, regardless of HIV viral load, are at increased risk of lethal infections with marrow-suppressive therapy including chemotherapy. Testing for HIV must be performed at sites mandated by local requirements.
Known human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study
Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study
Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study; note: HIV testing is not required for entry into this protocol
Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study
Patients with known human immunodeficiency virus (HIV) infection are ineligible due to risk of pharmacokinetic interactions between anti-retroviral therapy and the study drugs, as well as potential for significant immunosuppression and serious infections with mTOR inhibition
Patients known to be human immunodeficiency virus (HIV) positive and receiving highly active anti-retroviral therapy (HAART)
Known human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study
Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study; note: HIV testing is not required for entry into this protocol
Known human immunodeficiency virus (HIV)-positivity AND actively being treated with highly active anti-retroviral therapy (HAART)
Patients with a diagnosis of active human immunodeficiency virus (HIV) infection, on anti-retroviral therapy, or with a cluster of differentiation (CD) count less than  are ineligible due to potential interactions between irinotecan and anti-retroviral medications as well as possible immunosuppressive activity of the study treatment; testing is not required in the absence of clinical findings or suspicion
HIV-positive patients receiving anti-retroviral therapy are excluded from this study; HIV positive patients not receiving antiretroviral therapy are excluded
Individuals with a known history of human immunodeficiency virus (HIV) positivity may be included in the study as long as they are on appropriate highly active anti-retroviral therapy (HAART) therapy
Human immunodeficiency virus-positive patients receiving combination anti-retroviral therapy are excluded from the study
Human immunodeficiency virus (HIV) positive patients who are not on retroviral therapy will not be excluded from cohort , the normal liver function cohort\r\n* HIV positive patients who are not on retroviral therapy will be excluded from cohorts -
Human immunodeficiency virus (HIV)-positive patients receiving anti-retroviral therapy are excluded from this study
Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded
Human immunodeficiency virus (HIV) - positive participants receiving anti-retroviral therapy
Patients cannot be receiving HAART (highly active anti-retroviral therapy) therapy
Human immunodeficiency virus (HIV)-positive patients receiving anti-retroviral therapy are excluded from this study; HIV positive patients not receiving antiretroviral therapy are excluded
Known human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study
Known human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study
Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study